



CEDARS-SINAI MEDICAL CENTER.

CURRICULUM VITAE

Jethro L. Hu, M.D.

Faculty Neuro-oncologist
Department of Neurology
Department of Neurosurgery
Cedars-Sinai Medical Center

- Office:** 127 South San Vicente Boulevard, Suite A6600
Los Angeles CA 90048
Phone: 310.423.8100
Fax: 310.423.8189
- Email:** jethro.hu@cshs.org
- Education:** University of California at Berkeley, 1999
B.A., Molecular and Cell Biology, Division of Neurobiology (with honors)
B.A., Political Science
- University of California at San Francisco, M.D. 2004
- Training:** Santa Clara Valley Medical Center, Medical Internship 2004-2005
- University of California at Los Angeles, Neurology Residency 2005-2008
Chief Resident, 2007-2008
- Massachusetts General Hospital / Dana-Farber Cancer Institute,
Neuro-Oncology Fellowship 2008-2009
- Licensure:** California State Medical License, A94764
- Board Certification:** American Board of Psychiatry and Neurology, since 2008
- United Council of Neurological Subspecialties - Neuro-Oncology, since 2011
- Academic Appointments:**
- Faculty Neuro-oncologist, 2009 to present
Johnnie L. Cochran, Jr. Brain Tumor Center
Departments of Neurology and Neurosurgery
Cedars-Sinai Medical Center
- Professional Activities:**
- Core Member, Samuel Oschin Comprehensive Cancer Institute, 2012 - present
- CSMC Cancer Committee, 2014 -- present

Neuro-Oncology Beacon DBV Committee, 2015 -- present

Neuro-Oncology Clinical Algorithm Development Committee, 2014

Medical Staff Leadership Development Program, 2011- 2013

Member, Cedars-Sinai Code Brain Stroke Program, 2011-2012

Co-Chair, 'Outsmarting brain tumors: a conference on brain tumors for patients, families and caregivers', 5-14-11

Member, Brain Tumor Trials Collaborative, 2009 to present

Member, Brain Tumor Investigator Collaborative, 2009 to present

Member, Radiation Therapy Oncology Group, 2010 to present

Member, Cedars-Sinai Brain Tumor Center of Excellence, 2009 to present

Member, Society for Neuro-Oncology, 2010 to present

Member, American Society of Clinical Oncology, 2009 to present

Member, American Academy of Neurology, 2005 to present

Honors and Special Awards:

Cedars-Sinai Medical Center, Circle of Friends honoree, 2012 to 2015

American Academy of Neurology, Resident Scholarship, Annual Meeting, April 2008

Augustus S. Rose Award for Excellence in Teaching, UCLA Dept of Neurology, June 2008

'Best Research Poster', UCLA Neurology and Neuroscience Poster Session, June 2007

'Best Clinical Poster', UCLA Neurology and Neuroscience Poster Session, June 2006

Honors Distinction in General Scholarship, UC Berkeley, 1999

Departmental Honors, Molecular and Cell Biology (MCB), UC Berkeley, 1999

Outstanding Research Award, MCB Student Research Symposium, UC Berkeley, 1999

Dean's List, UC Berkeley, 1996 to 1999

Member, Golden Key Honor Society, UC Berkeley, 1997

Regent's Scholar, UC Berkeley, 1995 to 1999

Robert C. Byrd Scholar, UC Berkeley, 1995 to 1999

Research Experience / Protocol Development / Grants and Fellowships Received:

1. Principal Investigator, Investigator-initiated protocol: A phase I trial of vaccination with autologous dendritic cells pulsed with lysate derived from an allogeneic glioblastoma stem-

like cell line for patients with newly diagnosed or recurrent glioblastoma, December 2013 to present

Funded by the FasterCures Foundation

2. Principal Investigator, Investigator-initiated protocol: A phase I trial of vaccination with autologous dendritic cells pulsed with lysate derived from autologous stem-like cells for patients with newly diagnosed or recurrent glioblastoma (pending)
3. Principal Investigator, BTTC09-01: A phase I-II trial everolimus and sorafenib in patients with recurrent high-grade gliomas (pending)
4. Principal Investigator, Investigator-initiated protocol: A registry to evaluate correlation between CNS tumor biomarker expression patterns and clinical outcomes, June 2013 to present
5. Principal Investigator, Single-patient protocol: Compassionate use veliparib (ABT-888) for recurrent glioblastoma, 1-2-13 to 5-30-13
6. Principal Investigator, N0577: A Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1/19q Co-deleted Anaplastic Glioma, 8-9-10 to present
7. Principal Investigator, Investigator-initiated protocol: Assessment of Blood Brain Barrier Permeability Using Dynamic MR Imaging, Cedars-Sinai Research Institute, 7-1-10 to present
8. Fellow, K30 Graduate Training Program in Translational Investigation, UCLA, 2009 to 2011
Track 2 certification

Lectures/Presentations:

1. Invited speaker, Society for Brain Mapping and Therapeutics
'Crowdsourcing in Neuro-Oncology,' 3-8-15
2. SOCCI Multi-Disciplinary Tumor Board, 2-26-14, 10-29-14, 2-25-15
3. Invited speaker, Gynecologic Oncology Didactics
'CNS Oncologic Emergencies,' 2-19-14
4. Invited speaker, Graduate Program in Biomedical Science and Translational Medicine
'The Blood-Brain Barrier: A clinician's perspective', 7-31-13 & 7-30-14
5. Invited speaker, Neurosurgery Department Didactics
'Glioblastoma: A tour of the evidence', 4-26-13
'The Blood-Brain Barrier', 10-30-09
6. Invited speaker, Neurology Department Didactics,
'Neuro-Oncology Board Review', 4-10-13
'Neurobehavioral Syndromes and Dementias', 9-21-11
'The Blood-Brain Barrier', 10-18-13
7. Grand Rounds, Cedars-Sinai Departments of Neurology and Neurosurgery
'Brain Tumor Permeability Imaging', 4-13-12
8. Invited speaker, UCSD Neuro-Oncology Conference
'Beyond the Blood-Brain Barrier', 2-24-12
9. Platform Presentation, Society for Neuro-Oncology Annual Meeting

'Dendritic Cell Vaccine Therapy for Patients with Recurrent Glioblastoma: a single institution pooled analysis of four trials', 11-18-11

10. Invited speaker, Cedars-Sinai 'Lunch and Learn' series, 1-3-11
'So What Goes on in Brain Tumor Clinic Anyways?'

Boards:

Medical Director, The Cancerful Foundation. 2015 -- present

Advisory board member, Novocure. 2013 -- present

Expert consultant, Grand Rounds Health. 2013 -- present

Ad hoc reviewer: Molecular Biology Reports, Journal of Neuro-Oncology

BIBLIOGRAPHY

Original Reports:

1. Ozawa T*, **Hu J***, Hu LJ, Kong EL, Bollen AW, Lamborn KR, Deen DF: Functionality of hypoxia-induced BAX expression in a human glioblastoma xenograft model. *Cancer Gene Therapy*, 12, 449 - 455 (2005). *Co-first authored.
2. Carico C, Nuno M, Mukherjee D, Elramsisy A, Dantis J, **Hu J**, Rudnick J, Yu JS, Black KL, Bannykh SI, Patil CG: Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. *PLoS One*, 7(3):e33684 (2012)
3. Patil CG, Yi A, Elramsisy A, **Hu J**, Mukherjee D, Yu JS, Bannykh SI, Black K, Nuno M: Prognosis of patients with multifocal glioblastoma: A case-controlled study. *Journal of Neurosurgery* (2012)
4. Patil CG, Nuno M, Elramsisy A, Mukherjee D, Carico C, Dantis J, **Hu J**, Yu JS, Fan X, Black KL, Bannykh SI: High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era. *Neuro-Oncology* (2012)
5. **Hu J**, Wen PY, Abrey LE, Camilo F, Drappatz J, Salem N, Supko JG, Hochberg F: A phase II trial of oral gimatecan for recurrent glioblastoma. *Journal of Neuro-Oncology* (2013)
6. Saria M, Corle C, **Hu J**, Rudnick JD, Phuphanich S, Mrugula M, Fu DB, Bota D, Kim RY, Brown T, Feely H, Hu A, Lee JW, Carter B, Kesari S: Retrospective Analysis of the Efficacy and Tolerability of Lacosamide in Brain Tumor Patients. *Journal of Neurosurgery* (2013)
7. Mukherjee D, **Hu J**, Brien EW, Chu RM: Metastasis of an intracranial anaplastic meningioma to the clavicle: case report. (2014), submitted
8. Raizer JJ, Giglio P, **Hu J**, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yung A, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont I, DeGroot J, Aldape K, Gilbert MR, Brain Tumor Trials Collaborative: A Phase II study of Bevacizumab and Erlotinib after Radiation Therapy and Temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter methylation. *Neurology* (2015), submitted
9. Daley F, Eskenazi J, **Hu J**: NeuroImages IT MTX myelopathy. *Neuro-Images*, section of Neurology (2015), submitted
10. **Hu J**, Fan X, Patil C, Kesari S, Lill M: Salvage pemetrexed for refractory primary T-cell lymphoma of the central nervous system. *CNS Oncology* (2015), submitted

11. Sarmiento JM, Mukherjee D, Black K, Fan X, **Hu J**, Nuno M, Patil C: Do Long-Term Survivor Primary Glioblastoma Patients Harbor IDH1 Mutations? Journal of Neurological Surgery-Part A (2015), (CEN-2015-05-OA-1455), submitted manuscript

Reviews:

1. **Hu J**, Kesari S: The molecular basis for novel therapies. Cancer Journal 18(1), 32-39 (2012)
2. Patil CG, Eboli P, **Hu J**: Management of multi-focal/multi-centric glioma. Neurosurgery Clinics of North America, 23(2):343-50 (2012)
3. **Hu J**, Kesari S: Strategies for overcoming the blood-brain barrier for the treatment of brain metastases. CNS Oncology (2013)

Book Chapters:

1. **Hu J**, Kesari S: General aspects of chemotherapy including biologic agents. Neuro-Oncology, first edition, edited by Packer RJ and Schiff D (2012)

Abstracts:

1. **Hu J**, Hu L, Ruan H, Ozawa T, Deen DF: p21 protects glioblastoma cells against the cytotoxic effects of paclitaxel. American Association of Cancer Research Annual Meeting (2000).
2. **Hu J**, Ozawa T, Hu L, Deen DF: Hypoxia-inducible expression of BAX delays the growth of human brain tumors *in vivo*. Radiation Research Society Annual Meeting (2002).
3. **Hu J**, Wen PY, Abrey LE, Fadul C, Drappatz J, Salem N, Amato A, Carminati P, Supko J, Hochberg F: Phase II trial of oral gimatecan for adults with recurrent glioblastoma. Poster presentation, ASCO Annual Meeting (2009).
4. Rudnick JR, Wheeler CJ, Phuphanich S, Chu RM, Mazer M, Wang H, Serrano N, Nuno M, Richardson J, **Hu J**, Black KL, Yu JS: A phase I trial of surgical resection with biodegradable carmustine wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. SNO Annual Meeting (2010).
5. **Hu J**, Wheeler C, Phuphanich S, Rudnick J, Nuno M, Serrano N, Dantis J, Richardson J, Mazer M, Wang HQ, Chu R, Black K, Yu J: Dendritic cell vaccine immunotherapy improves survival for patients with newly diagnosed glioblastoma. SNO Annual Meeting (2010).
6. Rudnick JR, Bresee C, Rogatko A, Sakowsky S, Franco M, **Hu J**, Lim S, Lopez A, Yu L, Ryback K, Tsang V, Lill M, Steinberg A: The early experience with DR. BEAT: A phase IIa study of the addition of temozolomide to a standard conditioning regimen for autologous stem cell transplantation in relapsed and refractory central nervous system lymphoma. SNO Annual Meeting (2011).
7. Rudnick J, Bresee C, Rogatko A, Sakowsky S, Franco M, **Hu J**, Lim S, Lopez A, Ryback K, Tsang V, Lill M, Steinberg A: The early experience with Dr. BEAT: a phase IIA study of the addition of temozolomide to a standard conditioning regimen for autologous stem cell transplantation in relapsed and refractory CNS lymphoma. SNO Annual Meeting (2011).
8. **Hu J**, Patil C, Nuno M, Wheeler C, Rudnick J, Phuphanich S, Mazer M, Wang HQ, Chu R, Black K, Yu J: Dendritic cell vaccine therapy for patients with recurrent glioblastoma: a single-institution pooled analysis of four trials. SNO Annual Meeting (2011).

9. Nuno M, Nosova K, Carico C, Mukherjee D, Rudnick J, **Hu J**, Yu J, Black K, Patil C: Patterns of care and prognosis of patients with anaplastic astrocytoma. Congress of Neurological Surgeons Annual Meeting (2012).
10. Patil C, Carico C, Nuno M, Dantis J, Elramsisy A, Bannykh S, Mukherjee D, **Hu J**, Black K, Yu J: Loss of PTEN is not associated with poor survival in glioblastoma patients in the post-temozolomide era. American Association of Neurosurgeons (AANS) Annual Meeting (2012).
11. Patil C, Elramsisy, Nuno M, Dantis J, Carico C, Bannykh S, Mukherjee D, **Hu J**, Black K, Yu J: High levels of phosphorylated MAP kinase are associated with poor survival in newly diagnosed glioblastoma patients of the post-temozolomide era. AANS Annual Meeting (2012).
12. **Hu J**, Nosova K, Nuno M, Yi A, Elramsisy A, Mukherjee D, Rudnick K, Phuphanich S, Bannykh SI, Yu J, Black KL, Patil C: Retrospective analysis of glioblastoma patients treated with bevacizumab who presented with multifocal disease at diagnosis. ASCO Annual Meeting (2012).
13. Rudnick J, **Hu J**, Luptrawan A, Mazer M, Wheeler C, Nuno M, Chu R, Phuphanich S, Black K, Yu J: The final report of a phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with glioblastoma. ASCO Annual Meeting (2012).
14. **Hu J**, Nuno M, Patil CG, Rudnick J, Phuphanich S, Bannykh S, Chu R, Yu J, Black K: PTEN expression and response to bevacizumab: a single-institution retrospective analysis. SNO Annual Meeting (2012).
15. Phuphanich S, **Hu J**, Rudnick J, Chu R, Yu J, Naruse R, Ljubimova J, Sanchez C, Guevarra A, Naor R, Black K: Pilot study of phosphodiesterase-5 inhibitor (PDE-5) to increase intratumoral concentration of carboplatin in patients with recurrent high grade gliomas and brain metastases. SNO Annual Meeting (2012).
16. Raizer JJ, Giglio P, **Hu J**, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli V, Loghin M, Paleologos N, Yung A, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont I, DeGroot J, Gilbert MR: BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter methylation. ASCO Annual Meeting (2013).
17. Rudnick J, Ravi A, Sanchez C, **Hu J**, John Yu, Padmanee Sharma, Keith Black: A dramatic clinical and cytologic response to ipilimumab in a multi-drug regimen with bevacizumab. SNO Annual Meeting (2013).
18. Yu J, Rudnick J, **Hu J**, Phuphanich S, Mazer M, Wang HQ, Xu M, Nuno M, Patil C, Chu R, Black K, Wheeler C: Phase I/II trial of tumor lysate pulsed dendritic cell vaccine with a toll-like receptor 7 (TLR7) agonist for patients with glioblastoma. SNO Annual Meeting (2013).
19. Phuphanich S, Wheeler C, Rudnick J, **Hu J**, Mazer M, Wang HQ, Nuno M, Sanchez C, Fan X, Ji J, Chu R, Bender J, Hawkins E, Black K, Yu J: Long term remission over 5 years in patients with newly diagnosed glioblastoma treated with ICT-107 vaccine: a follow-up study. SNO Annual Meeting (2013).
20. Sarmiento JM, Ly D, Ortega A, Jutla J, Carico C, Dickinson H, Patil CG, **Hu J**: Efficacy of bevacizumab at first vs. subsequent recurrence: a single institution retrospective analysis. SNO Annual Meeting (2013).
21. **Hu J**, Sharma P, Yu J, Black K, Rudnick J: Ipilimumab for recurrent glioblastoma: A single-institution case series. ASCO Annual Meeting (2014).

22. **Hu J**, Yu J, Black K, Rudnick J: Ipilimumab for recurrent glioblastoma: A single-institution case series. SNO Annual Meeting (2014).
23. Kesari S, Xiu J, **Hu J**, Salacz M, Piccioni D, Reddy S: Tumor profiles of brain metastases from NSCLC, breast cancer, and melanoma. Poster presentation, ASCO Annual Meeting (2015).
24. Xiu J, Spetzler D, Bender R, Ghazalpour A, Gatalica Z, Reddy S, Piccioni D, **Hu J**, Glantz M, Kesari S: Tumor profiling on 1245 gliomas and paired tumor study on 19 high grade gliomas. Poster presentation, ASCO Annual Meeting (2015).
25. Mark G, **Hu J**, Yung A, Grimm S, Tremont I, Avgeropoulos N, Walbert T, Loghin, M, Penas-Prado M: A phase I trial everolimus and sorafenib in patients with recurrent high-grade gliomas: Brain Tumor Treatment Collaborative trial 09-01. ASCO Annual Meeting (2015).